摘要
目的从细胞分子生物学角度探讨DNA拓扑异构酶(TopoII)在恶性胶质瘤多药耐药中的作用。方法应用流式细胞仪对20例原发与20例复发恶性胶质瘤术后标本中DNA拓扑异构酶进行测定,对照研究。结果20例复发恶性胶质瘤中DNA拓扑异构酶的表达量较20例原发者明显减少(P<0.05)。结论恶性胶质瘤在治疗过程中获得多药耐药性可能是由于DNA拓扑异构酶数量的减少或活性降低造成的。
Objective To explore the relationship between DNA topoisomerase act ivity and multidrug resistance in human glioma. Methods DNA topoisomerase activ ities were measured in 20 samples of fresh primary glioma tissues and 20 samples of recurrence malignant glioma from posttreated patients by flow cytometry (FCM ). Results The expression of DNA topoisomerase in recurrence malignatn glioma s ignificantly decreased than in primary malignant glioma(P<0.05) Conclusion Decr eased topoisomerase activity and (or) numbers may be another factor in multidrug resistance.
出处
《实用医药杂志》
2003年第6期445-446,共2页
Practical Journal of Medicine & Pharmacy
